Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA (NASDAQ: NVDA). A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stake in Recursion Pharmaceuticals. This move has been interpreted by the market as a strong endorsement of Recursion's potential and its unique use of AI in drug discovery, leading to a surge in demand for Recursion Pharmaceuticals stock. The question remains whether Recursion truly deserves this newfound attention or if the market reaction is simply an overreaction to the news.
